Juvenile Sexual Offending: An EU Prevalence and State Response Study: Study Protocol

Background: Juvenile sexual offending is an area that has been largely under-researched to date and this has resulted in very little and sometimes conflicting research being published in the area. The dearth of empirical data in the space is concerning as it suggests that policy may not be underpinned by an empirical framework and this has far reaching implications for the development of laws, intervention programmes and the management of young people accused/convicted of a juvenile sexual offence. Moreover, the lack of an evidence-based framework has the potential to contribute to misinformation amongst the public who may be relying upon anecdotal news reports and exaggerated media representations. Methods/Design: This study will use a survey to collect the same data from each European member state with the aim of generating comparable data. The first step in the design process was to design a typology of juvenile sexual offences so the data collected represents the same offences across each jurisdiction. The second step in the design process is to design a survey, using the typology, to collect data across each member country. Discussion: This study aims to take a first step towards generating comparable data across each member state. As such this project will be the first to generate accurate comparable data on the prevalence of juvenile sexual offending across each EU Member State and data on how each Member State reacts to juvenile sexual offending

Medium-term real-world data for erenumab in 177 treatment resistant or difficult to treat chronic migraine patients: persistence and patient reported outcome measures after 17–30 months

Abstract Background Many migraine patients do not respond adequately to conventional preventive treatments and are therefore described as treatment/medically resistant or difficult to treat cases. Calcitonin gene-related peptide monoclonal antibodies are a relatively novel molecular treatment for episodic and chronic migraine that have been shown to be effective in short duration clinical trials in approximately 40–50% of all chronic migraine patients. Patient Related Outcome Measures (PROM) or Quality of Life (QoL) questionnaires are used to help measure response to treatment in migraine. Although some open label extension studies have become available for erenumab, there is a lack of real-world data pertaining to quality of life in the medium to long-term for chronic and treatment resistant migraine patients. Methods A total of 177 treatment resistant CM patients were started on erenumab (70 mg or 140 mg subcutaneous injection every 4 weeks) in our three specialist Headache Clinics. Of these, 174 had their first injection between December 2018 and October 2019. All patients were evaluated with the following PROM: the Headache Impact Test− 6, Migraine Associated Disability Assessment test and Migraine-Specific QoL Questionnaire, before starting treatment with erenumab and at intervals of 3–12 months after starting treatment. The decision to continue treatment was based on subjective clinical improvement of at least 30% (as reported by the patient), supported with diaries and QoL questionnaires. We present here the QoL measurements for this group of 177 patients. Prior preventive migraine treatments included conventional oral prophylactic medications (such as topiramate, candesartan, propranolol, or amitriptyline), at least two cycles of PREEMPT protocol onabotulinumtoxin A or (in a small number of cases) neuromodulation with single pulse Transcranial Magnetic Stimulation. Results Of the 177 patients who started treatment with erenumab, 68/177 (38.4%) stopped during the first year, either due to lack of efficacy (no significant benefit or only minimal improvement) and/or possible side effects. 109/177 (61.6%) patients reported clinically significant improvement after 6–12 months and wished to stay on treatment. Twelve of these 109 patients subsequently stopped treatment in the period between 1 year and up to June 2021 (mainly due to a worsening of their migraine). Therefore, a total of 97/177 patients (54.8%) remained on treatment as of June 2021 (duration of treatment 17–30 months, median of 25 months). Conclusion Approximately 55% of treatment resistant or difficult to treat CM patients who trialled erenumab in our clinics reported a subjective benefit and were still on treatment after 17–30 months